Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: The effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy

Clinical and Translational Allergy

Volumn 2, Issue 1, 2012, Pages

  Jacobsen, Lars ^a,b   Wahn, Ulrich ^c   Bilo, M Beatrice ^d  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b Allergy Learning and Consulting   (Denmark)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

Allergy; Antibodies; Asthma; IgE; IgG; Immunological mechanisms; Long term effect; Prevention; Rhinitis; Specific immunotherapy

Indexed keywords

ALLERGEN; GAMMA INTERFERON; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; PLACEBO; POLLEN ANTIGEN; STEROID; UNCLASSIFIED DRUG;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ASTHMA; BRONCHUS HYPERREACTIVITY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; PALLIATIVE THERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; REVIEW; RHINOCONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYMPTOM; TH2 CELL;

EID: 84978025371     PISSN: None     EISSN: 20457022     Source Type: Journal    
DOI: 10.1186/2045-7022-2-8     Document Type: Review

References (110)

1. Nose and lung cross-talk in allergic airways disease. Braunstahl GJ, Prins JB, Kleinjan A, Overbeek SE, Hoogsteden HC, Fokkens WJ, Clin Exp All Rev 2003 3 38 42 10.1046/j.1472-9725.2003.00060.x (Pubitemid 36241363)
2. Mechanisms of nose-lung interaction. Togias A, Allergy 1999 54 Suppl 57 94 105 10565484 (Pubitemid 29493660)
3. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, Ohta K, Price D, Bousquet J, Allergy 2007 62 Suppl 84 1 41 17567449 (Pubitemid 47556484)
4. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, et al. Allergy 2008 63 Suppl 86 8 160 18331513 (Pubitemid 351357811)
5. Allergic rhinitis in school-aged children with asthma-still under-diagnosed and under-treated? A retrospective study in a children's hospital. Ruokonen M, Kaila M, Haataja R, Korppi M, Paassilta M, Pediatr Allergy Immunol 2010 21 149 e154 10.1111/j.1399-3038.2009.00891.x 19594853
6. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Bousquet J, Gaugris S, Kocevar VS, Zhang Q, Yin DD, Polos PG, Bjermer L, Clin Exp Allergy 2005 35 723 727 10.1111/j.1365-2222.2005.02251.x 15969661 (Pubitemid 40961343)
7. The link between allergic rhinitis and allergic asthma: a prospective population-based study. Linneberg A, Henrik NN, Frolund L, Madsen F, Dirksen A, Jorgensen T, The Copenhagen Allergy Study Allergy 2002 57 1048 1052 (Pubitemid 35238642)
8. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Settipane RJ, Hagy GW, Settipane GA, Allergy Proc 1994 15 21 25 10.2500/108854194778816634 8005452
9. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, et al. J Allergy Clin Immunol 2002 109 251 256 10.1067/mai.2002.121317 11842293 (Pubitemid 34158289)
10. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, Bagnasco M, Canonica GW, J Allergy Clin Immunol 1995 96 971 979 10.1016/S0091-6749(95)70235-0 8543756 (Pubitemid 26015659)
11. Age-dependent tendency to become sensitized to other classes of aeroallergens in atopic asthmatic children. Silvestri M, Rossi GA, Cozzani S, Pulvirenti G, Fasce L, Ann Allergy Asthma Immunol 1999 83 335 340 10.1016/S1081-1206(10)62674-9 10541426 (Pubitemid 29503669)
12. Pets in the home and the development of pet allergy in adulthood. Linneberg A, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jorgensen T, The Copenhagen Allergy Study Allergy 2003 58 21 26 (Pubitemid 36259536)
13. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual. Cox L, Wallace D, Immunol Allergy Clin North Am 2011 31 561 599 10.1016/j.iac.2011.05.001 21737043
14. Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. Jacobsen L, Ann Allergy Asthma Immunol 2001 87 43 46 11476475 (Pubitemid 32661329)
15. Prophylactic inoculation against hay fever. Noon L, Lancet 1911 177 1572 1573 10.1016/S0140-6736(00)78276-6
16. Immunological mechanisms of allergen-specific immunotherapy. Larche M, Akdis CA, Valenta R, Nat Rev Immunol 2006 6 761 771 10.1038/nri1934 16998509 (Pubitemid 44453462)
17. Future forms of immunotherapy. Casale TB, Stokes JR, J Allergy Clin Immunol 2011 127 8 15 10.1016/j.jaci.2010.10.034 21094518
18. Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. Committee for Medicinal Products for Human Use, European Medicines Agency 2008 http://www.ema.europa.eu/ docs/en/GB/document/library/Scientific/guideline/2009/09/WC500003605.pdf
19. Guideline on Allergen Products: Production and Quality Issues. Committee for Medicinal Products for Human Use, European Medicines Agency 2008 http://www.ema.europa.eu/docs/en/GB/document/library/Scientific/guideline/2009/ 09/WC500003333.pdf
20. Allergic rhinitis and its impact on asthma. Bousquet J, Van Cauwenberge P, Khaltaev N, J Allergy Clin Immunol 2001 108 147 S334 10.1067/mai.2001.118891 11707753
21. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, Valovirta E, Allergy 2007 62 317 324 10.1111/j.1398-9995.2006.01312.x 17298350
22. GINA Report, Global Strategy for Asthma Management and Prevention. Batemann ED, GINA No 95-3659 National Heart, Lung and Blood Institute, National Institute of Health 2009 1 92
23. Update on mechanisms of allergen injection immunotherapy. James LK, Durham SR, Clin Exp Allergy 2008 38 1074 1088 10.1111/j.1365-2222.2008.02976.x 18691292
24. Immunological mechanisms of sublingual allergen-specific immunotherapy. Novak N, Bieber T, Allam JP, Allergy 2011 66 733 739 10.1111/j.1398-9995.2010. 02535.x 21251016
25. Mechanisms of immunotherapy to aeroallergens. Shamji MH, Durham SR, Clin Exp Allergy 2011 41 1235 1246 10.1111/j.1365-2222.2011.03804.x 21762223
26. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. Passalacqua G, Durham SR, J Allergy Clin Immunol 2007 119 881 891 10.1016/j.jaci.2007.01.045 17418661 (Pubitemid 46527840)
27. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. Rak S, Lowhagen O, Venge P, J Allergy Clin Immunol 1988 82 470 480 10.1016/0091-6749(88)90021-8 3170995
28. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR, Allergy 1995 50 405 413 10.1111/j.1398-9995.1995.tb01170.x 7573829
29. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR, J Allergy Clin Immunol 2001 107 87 93 10.1067/mai.2001.112027 11149996 (Pubitemid 32105250)
30. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen [see comments]. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O, Clin Exp Allergy 1997 27 1007 1015 10.1111/j.1365-2222.1997.tb01252.x 9678832 (Pubitemid 27421829)
31. Increases in IL-12 messenger RNA + cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy [see comments]. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR, J Allergy Clin Immunol 1997 99 254 260 10.1016/S0091-6749(97)70106-4 9042055 (Pubitemid 27091578)
32. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. Wilson DR, Nouri-Aria KT, Walker SM, Pajno GB, O'Brien F, Jacobson MR, Mackay IS, Durham SR, J Allergy Clin Immunol 2001 107 971 976 10.1067/mai.2001.115483 11398073 (Pubitemid 32523335)
33. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, Durham SR, Immunology 2002 105 56 62 10.1046/j.1365-2567.2002.01338.x 11849315 (Pubitemid 34128040)
34. Specific immunotherapy and turning off the T cell: how does it work? Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA, Ann Allergy Asthma Immunol 2011 107 381 392 10.1016/j.anai.2011.05.017 22018608
35. Immunoglobulin G4: an odd antibody. Aalberse RC, Stapel SO, Schuurman J, Rispens T, Clin Exp Allergy 2009 39 469 477 10.1111/j.1365-2222.2009.03207.x 19222496
36. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, Jacobson MR, Kimber I, Till SJ, Durham SR, J Allergy Clin Immunol 2011 127 509 516 10.1016/j.jaci.2010.12.1080 21281875
37. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA, J Allergy Clin Immunol 1996 97 1356 1365 10.1016/S0091-6749(96)70205-1 8648033 (Pubitemid 26192287)
38. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Savolainen J, Jacobsen L, Valovirta E, Allergy 2006 61 1184 1190 10.1111/j.1398-9995.2006.01206.x 16942566 (Pubitemid 44326353)
39. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR, J Immunol 2004 172 3252 3259 14978133 (Pubitemid 38263717)
40. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, Till SJ, J Allergy Clin Immunol 2008 121 1120 1125 10.1016/j.jaci.2008.01.072 18374405
41. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA, Eur J Immunol 2003 33 1205 1214 10.1002/eji.200322919 12731045 (Pubitemid 36609138)
42. Tregs and allergic disease. Robinson DS, Larché M, Durham S, J Clin Invest 2004 114 1389 1397 15545986 (Pubitemid 40385566)
43. Mechanisms of allergen-specific immunotherapy. Akdis CA, Akdis M, J Allergy Clin Immunol 2011 127 18 27 10.1016/j.jaci.2010.11.030 21211639
44. Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils. Kepley CL, Cambier JC, Morel PA, Lujan D, Ortega E, Wilson BS, Oliver JM, J Allergy Clin Immunol 2000 106 337 348 10.1067/mai.2000.107931 10932079 (Pubitemid 30645009)
45. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Wurtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H, Clin Exp Allergy 2008 38 8 1290 1301 10.1111/j.1365-2222.2008.03020.x 18510696 (Pubitemid 352019667)
46. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. Wachholz PA, Soni NK, Till SJ, Durham SR, J Allergy Clin Immunol 2003 112 915 922 10.1016/S0091-6749(03)02022-0 14610480 (Pubitemid 37412059)
47. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. van Neerven RJ, Knol EF, Ejrnaes A, Wurtzen PA, Int Arch Allergy Immunol 2006 141 119 129 10.1159/000094714 16864979 (Pubitemid 44413287)
48. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H, J Immunol 1999 163 2944 2952 10453043 (Pubitemid 29399227)
49. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, Pitkin L, Pilette C, Nouri-Aria K, Durham SR, Clin Exp Allergy 2010 40 598 606 20184605
50. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A, J Allergy Clin Immunol 2011 128 791 799 10.1016/j.jaci.2011. 03.049 21620452
51. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A, Allergy 2005 60 801 807 10.1111/j.1398-9995.2005.00790.x 15876311 (Pubitemid 40769884)
52. The safety and efficacy of subcutaneous birch pollen immunotherapy-a one-year, randomised, double-blind, placebo-controlled study. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ, Allergy 2002 57 297 305 10.1034/j.1398-9995.2002. 1o3532.x 11906359 (Pubitemid 34280656)
53. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Arvidsson MB, Lowhagen O, Rak S, Allergy 2004 59 74 80 15245363 (Pubitemid 38167955)
54. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis. Williams A, Henzgen M, Rajakulasingam K, Eur Ann Allergy Clin Immunol 2007 39 123 126 17523386 (Pubitemid 46732364)
55. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Frew AJ, Powell RJ, Corrigan CJ, Durham SR, J Allergy Clin Immunol 2006 117 319 325 10.1016/j.jaci.2005.11.014 16461133 (Pubitemid 43190146)
56. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. Garcia-Robaina JC, de la TF, Sanchez I, Fernandez-Caldas E, Casanovas M, J Allergy Clin Immunol 2006 118 1026 1032 10.1016/j.jaci.2006.07.043 17088125 (Pubitemid 44666986)
57. Long-term clinical efficacy of grass-pollen immunotherapy [see comments]. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT, N Engl J Med 1999 341 468 475 10.1056/NEJM199908123410702 10441602 (Pubitemid 29372886)
58. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R, J Allergy Clin Immunol 2010 125 131 138 10.1016/j.jaci.2009. 10.035 20109743
59. Allergen injection immunotherapy for seasonal allergic rhinitis. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S, Cochrane Database of Systematic Reviews 2007 1 D001936 DOI: 10.1002/14651858.CD001936.pub2 (Pubitemid 351820381)
60. Sublingual immunotherapy for allergic rhinitis. Radulovic S, Calderon MA, Wilson D, Durham S, Cochrane Database of Systematic Reviews 2010 12 D002893 DOI: 10.1002/14651858.CD002893.pub2
61. Injection allergen immunotherapy for asthma. Abramson MJ, Puy RM, Weiner JM, Cochrane Database of Systematic Reviews 2010 8 D001186 DOI: 10.1002/14651858.CD001186.pub2
62. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Blumberga G, Groes L, Haugaard L, Dahl R, Allergy 2006 61 843 848 10.1111/j.1398-9995.2006.01088.x 16792582 (Pubitemid 43893985)
63. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. Zielen S, Kardos P, Madonini E, J Allergy Clin Immunol 2010 126 942 949 10.1016/j.jaci.2010.06.002 20624650
64. Allergic rhinitis in patients with asthma: the Swiss LARA (Link Allergic Rhinitis in Asthma) survey. Taegtmeyer AB, Steurer-Stey C, Spertini F, Bircher A, Helbling A, Miedinger D, Schafroth S, Scherer K, Leuppi JD, Curr Med Res Opin 2009 25 1073 1080 10.1185/03007990902820733 19292600
65. Effects of inhaled steroids on growth, bone metabolism and adrenal function. Allen DB, Expert Rev Respir Med 2007 1 65 74 10.1586/17476348.1.1.65 20477267
66. Primary and secondary endpoints in clinical trials. Jacobsen L, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2009 96 96 104 20799449
67. Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials? Pfaar O, Kleine-Tebbe J, Hormann K, Klimek L, Immunol Allergy Clin North Am 2011 31 289 309 x 10.1016/j.iac.2011.02.004 21530821
68. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Hoiby AS, Strand V, Robinson DS, Sager A, Rak S, Clin Exp Allergy 2010 40 1062 1070 10.1111/j.1365-2222.2010.03521.x 20642579
69. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Pfaar O, Robinson DS, Sager A, Emuzyte R, Allergy 2010 65 1614 1621 10.1111/j.1398-9995.2010.02413.x 20645937
70. Prospective validation of 'Allergy-Control-SCORE(TM)': a novel symptom-medication score for clinical trials. Hafner D, Reich K, Matricardi PM, Meyer H, Kettner J, Narkus A, Allergy 2011 66 629 636 10.1111/j.1398-9995.2010. 02531.x 21261656
71. Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials. Durham SR, Birk AO, Andersen JS, Allergy 2011 66 120 123 10.1111/j.1398-9995.2010.02434.x 20608918
72. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs [see comments]. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR, BMJ 1991 302 265 269 10.1136/bmj.302.6771.265 1998791
73. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ, Clin Exp Allergy 1997 27 860 867 10.1111/j.1365-2222.1997.tb01225.x 9291281 (Pubitemid 27359850)
74. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR, J Allergy Clin Immunol 2006 118 434 440 10.1016/j.jaci.2006.05.003 16890769 (Pubitemid 44160721)
75. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, de BO, Andre C, Melac M, J Allergy Clin Immunol 2007 120 1338 1345 10.1016/j.jaci.2007.07.046 17935764 (Pubitemid 350225683)
76. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR, Allergol Immunopathol (Madr) 2003 31 270 277 10.1157/13052432 (Pubitemid 37429027)
77. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, von Weikersthal-Drachenberg KJ, Allergy Asthma Proc 2011 32 239 247 10.2500/aap.2011.32.3453 21535913
78. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Balda BR, Wolf H, Baumgarten C, Klimek L, Rasp G, Kunkel G, Muller S, Mann W, Hauswald B, Heppt W, et al. Allergy 1998 53 740 748 9722222 (Pubitemid 28374754)
79. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity. Klimek L, Mewes T, Wolf H, Hansen I, Schnitker J, Mann WJ, Otolaryngol Head Neck Surg 2005 133 538 543 10.1016/j.otohns.2005.07.020 16213926 (Pubitemid 41431842)
80. Hypoallergenic preparations in SCIT. Immunological features and their impact on clinical efficacy and safety, exemplary for the allergoids Allergovit Acaroid and a folding variant of the recombinant birch pollen major allergen Bet v 1. Brehler R, Kahlert H, Thum Oltmer S, Allergo Journal 2010 19 477 484
81. Allergen-specific immunotherapy with recombinant grass pollen allergens. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O, J Allergy Clin Immunol 2005 116 608 613 10.1016/j.jaci.2005.06.004 16159631 (Pubitemid 41267135)
82. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. Hedlin G, Graff Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow K, Sundin B, Lowenstein H, J Allergy Clin Immunol 1991 87 955 964 10.1016/0091-6749(91)90417-M 2026846
83. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. Haugaard L, Dahl R, Jacobsen L, J Allergy Clin Immunol 1993 91 709 722 10.1016/0091-6749(93)90190-Q 8454793 (Pubitemid 23110716)
84. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Pichler CE, Marquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M, Pichler WJ, Allergy 1997 52 274 283 10.1111/j.1398-9995.1997.tb00991.x 9140517 (Pubitemid 27166228)
85. Allergen-induced airway inflammation and its therapeutic intervention. O'Byrne PM, Allergy Asthma Immunol Res 2009 1 3 9 10.4168/aair.2009.1.1.3 20224664
86. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R, Zielen S, Clin Exp Immunol 2010 160 403 410 10.1111/j.1365-2249.2010.04106.x 20345983
87. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Riis B, Gronager PM, Durham SR, J Allergy Clin Immunol 2008 121 512 518 10.1016/j.jaci.2007.10.039 18155284
88. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M, Allergy 1996 51 489 500 8863926 (Pubitemid 26254936)
89. Five-year follow up on the PAT study: Specific immunotherapy and long-term prevention of asthma in children. Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Koller DY, Norberg LA, Urbanek R, et al. Allergy 2006 61 855 859 10.1111/j.1398-9995.2006.01068.x 16792584 (Pubitemid 43893987)
90. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Norberg LA, Valovirta E, Wahn U, et al. Allergy 2007 62 943 948 10.1111/j.1398-9995.2007.01451.x 17620073 (Pubitemid 47037870)
91. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, et al. J Allergy Clin Immunol 2012 129 3 717 725 10.1016/j.jaci.2011.12.973 22285278
92. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Mosbech H, Osterballe O, Allergy 1988 43 523 529 10.1111/j.1398-9995.1988.tb01631.x 3148282
93. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Jacobsen L, Nuchel PB, Wihl JA, Lowenstein H, Ipsen H, Allergy 1997 52 914 920 10.1111/j.1398-9995. 1997.tb01251.x 9298176 (Pubitemid 27375009)
94. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C, Lowenstein H, J Allergy Clin Immunol 1995 96 879 885 10.1016/S0091-6749(95)70223-7 8543744 (Pubitemid 26015648)
95. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Des-Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P, Bousquet J, V Duration of the efficacy of immunotherapy after its cessation Allergy 1996 51 430 433
96. Considerable 6 years post treatment long-term effect of pre-seasonal subcutaneous specific immunotherapy (SCIT) with a high-dose hypoallergenic grass pollen preparation. [abstract]. Kettner J, Mussler S, Narkus A, Häfner D, Allergy 2011 66 296
97. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Eng PA, Reinhold M, Gnehm HP, Allergy 2002 57 306 312 10.1034/j.1398-9995.2002. 1o3264.x 11906360 (Pubitemid 34280657)
98. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP, Allergy 2006 61 198 201 10.1111/j.1398-9995.2006.01011.x 16409196 (Pubitemid 43381830)
99. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De ME, Burastero SE, Calori G, Benetti L, Bonazza P, et al. J Allergy Clin Immunol 2004 114 851 857 10.1016/j.jaci.2004.07.012 15480326 (Pubitemid 39330257)
100. The value of hyposensitization therapy for bronchial asthma in children-a 14-year study. Johnstone DE, Dutton A, Pediatrics 1968 42 793 802 5685362
101. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness [In Process Citation]. Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA, Am J Respir Crit Care Med 2000 162 2048 2052 11112112 (Pubitemid 32051662)
102. Value of hyposensitization therapy for perennial bronchial asthma in children. Johnstone DE, Crump L, Pediatrics 1961 61 44
103. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract VI Specific immunotherapy prevents the onset of new sensitizations in children. Des-Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J, J Allergy Clin Immunol 1997 99 450 453 10.1016/S0091-6749(97)70069-1 9111487 (Pubitemid 27173080)
104. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S, A six-year follow-up study Clin Exp Allergy 2001 31 1392 1397 (Pubitemid 32823876)
105. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. Purello-D'Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, Ricciardi L, A retrospective study Clin Exp Allergy 2001 31 1295 1302 (Pubitemid 34208970)
106. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G, Allergy 2004 59 1205 1210 10.1111/j.1398-9995.2004.00508.x 15461603 (Pubitemid 39389476)
107. Prevention of Allergy and Allergic Asthma. World Health Organization, WHO report 2002
108. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1998 9 116 124 10.1111/j.1399-3038.1998.tb00356.x 9814724
109. Intermittent inhaled corticosteroids in infants with episodic wheezing. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F, N Engl J Med 2006 354 1998 2005 10.1056/NEJMoa054692 16687712
110. Long-term inhaled corticosteroids in preschool children at high risk for asthma. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, Lemanske RF, Strunk RC, Allen DB, et al. N Engl J Med 2006 354 1985 1997 10.1056/NEJMoa051378 16687711